Private equity and strategic consolidators continue to view ophthalmology as one of the most attractive physician practice segments in 2026. The specialty combines procedural economics, demographic tailwinds, and ancillary revenue streams that create significant value for investors. As the market for independent ophthalmology practices tightens, understanding current valuation benchmarks has become essential for practice owners evaluating partnership opportunities, unsolicited offers, or strategic planning decisions.
Medical practices in 2025–2026 generally transact at 6x–12x EBITDA depending on size and specialty; however, ophthalmology practices—particularly scaled platforms—can achieve multiples at the high end of this range due to strong procedural economics and ancillary revenue opportunities.
This report provides standardized valuation ranges for ophthalmology practices. Whether you’re exploring a potential sale, benchmarking an inbound offer, or planning for long-term growth, these metrics offer a framework for understanding where your practice sits in today’s M&A landscape.
All valuation guidance is based on cited sources and internal knowledge. Actual pricing varies with each transaction and is based on many factors. Thus, information in this article is intended for educational purposes only and is not a guarantee of any outcome.
Ophthalmology practices typically trade within the following ranges in 2026:
| Platform Transactions (Initial Platform Investments, PE Exits, Large Practice Transactions) | Add-On Transactions (Bolt-On Acquisitions |
|---|---|
| EBITDA Multiple: 10–15× Revenue Multiple: ~1.0–3× Typical Profile: Large groups with established infrastructure, management depth, and significant ancillary revenue | EBITDA Multiple: 6–10× Revenue Multiple: ~1.0–3× Typical Profile: Small and mid-sized practices acquired by existing ophthalmology platforms to expand geographic coverage or clinical capabilities. |
Sources: HealthFMV, Sofrer Advisors, guidance from internal FOCUS bankers
The substantial gap between platform and add-on multiples reflects the infrastructure premium that buyers place on scale, management systems, and operational maturity. Buyers often pay several multiple turns higher for platform groups.
Ophthalmology continues to attract strong buyer interest due to a combination of demographic tailwinds, procedural profitability, and scalable ancillary revenue models. The aging population, particularly patients over 65, drives sustained demand for cataract surgery, glaucoma treatment, and retinal care, while premium procedures such as LASIK and advanced intraocular lenses create additional cash-pay revenue streams.
Practices with integrated services such as ambulatory surgery centers (ASCs), optical dispensaries, and diagnostic imaging benefit from multiple revenue streams and higher margins, making them especially attractive to private equity and strategic buyers.
Several factors consistently push ophthalmology practices toward the upper end of valuation ranges:
ASC ownership remains the single most impactful value driver in ophthalmology M&A. Practices with owned surgery centers benefit from:
Ancillary services such as ASCs, imaging, and optical dispensaries can represent 25–40% of total revenue in well-developed practices, significantly enhancing margin profile and valuation.
Retina-focused practices and comprehensive ophthalmology groups with significant retina capabilities can command premium valuations due to:
The 2024 acquisition of Retina Consultants of America by Cencora for $4.6 billion at an 18.4× EBITDA multiple underscores the strategic value pharmaceutical distributors place on retina platforms. Strategic buyers (McKesson, Cencora) have continued to acquire retina platforms into 2026.
Practices that have diversified beyond traditional clinic visits may achieve higher multiples by demonstrating:
This diversification reduces buyer risk by decreasing dependence on any single reimbursement stream and creates multiple expansion vectors for growth.
The composition and age profile of the physician group significantly impacts valuation:
Practices with senior-heavy partner groups approaching retirement without documented succession plans typically face valuation discounts unless they can demonstrate strong recruiting pipelines.
Size matters in ophthalmology M&A. Larger practices with professional management infrastructure consistently attract higher multiples because they reduce buyer integration risk and demonstrate scalability.
Larger practices can benefit from scale through centralized operations, stronger payer negotiating leverage, and diversified revenue streams, which reduce operational risk and support premium valuation multiples. Valuation multiples tend to increase with scale, reflecting reduced operational risk, stronger infrastructure, and greater buyer competition for platform-quality assets.
| EBITDA Range | Typical Valuation Range (EV/EBITDA) | Buyer Profile | Practice Characteristics |
|---|---|---|---|
| Under $1 Million | 5–6.5× | Physician-to-physician transactions or small tuck-ins | Single-site practices without ASC ownership; limited management infrastructure |
| $1–3 Million | 7–9× | Add-on acquisitions for existing platforms | Mid-sized groups with modest ancillaries; emerging operational systems |
| $3–5 Million | 9–11× | Emerging platform or larger add-on | Multi-site operations with ASC ownership; partial management infrastructure |
| $5+ Million | 10–15×+ | Platform-ready organization | Established management depth, multiple ASCs, sophisticated compliance and billing systems |
Buyers underwrite future cash flows, not historical performance alone. Practices that articulate credible growth plans may achieve premium valuations by demonstrating:
Practices that can document historical execution of growth initiatives (new locations, successful physician or OD additions, ancillary service launches) earn credibility with buyers and justify forward-looking valuation premiums.
Practices seeking top-quartile outcomes should focus on:
| Category | Focus Area | Key Actions to Maximize Valuation |
|---|---|---|
| Financial Optimization | Ensure earnings are credible and defensible | • Normalize EBITDA with clear add-backs • Reset owner compensation to fair-market provider rates • Remove personal or one-time expenses • Prepare pro forma adjustments buyers will accept in diligence |
| Operational Excellence | Demonstrate strong infrastructure and compliance | • Document management systems and SOPs • Track KPIs monthly with trend analysis • Maintain clear physician contracts with transparent compensation and non-compete terms • Maintain compliance policies, training programs, and audit readiness |
| Growth Narrative | Present a credible forward plan | • Build a three-year strategic plan • Include a market opportunity analysis showing expansion runway • Outline capital investments for ASC development, equipment, and technology • Highlight execution on prior growth initiatives |
| Competitive Process | Leverage buyer interest through structure and representation | • Engage an investment banker to run a structured auction • Conduct targeted outreach to financial and strategic acquirers • Secure multiple term sheets to create competitive tension • Maintain negotiation leverage through qualified alternatives |
Several macro trends are shaping ophthalmology practice valuations in 2026:
| Macro Trend | Market Impact | Key Takeaways |
|---|---|---|
| Heightened Buyer Competition | Many PE platforms are vying for fewer remaining independent practices. | • Auctions are likely to attract multiple bidders • Buyers are often willing to stretch valuations for scarce assets, especially larger practices in active locations • Creative structures (earnouts) are becoming more common • Speed and certainty of close now a differentiator |
| Strategic Buyer Entry | Pharmaceutical distributors and other strategic buyers increasingly target ophthalmology for vertical integration. | • Control of drug distribution and specialty pharmacy • Care coordination for chronic disease management • Access to clinical and outcomes data • Strategic buyers may pay premiums when clear synergies exist |
| Interest Rate Environment | Higher interest rates have normalized peak 2021–2023 multiples, but core fundamentals keep valuations strong. | • Proven ophthalmology platform models attract lenders • Vision care seen as recession-resistant • Operational efficiency supports leverage • Demographic tailwinds sustain buyer conviction |
Ophthalmology practices consistently rank among the highest-valued physician specialty segments, with platform transactions typically achieving 10–15× EBITDA and add-on acquisitions trading at 6–10× EBITDA in 2026. ASC ownership, retina specialization, multiple revenue streams, and favorable physician demographics drive valuations toward the upper end of these ranges.
Scale matters: practices crossing $3–5 million in EBITDA with professional management infrastructure often capture 2–4 additional multiple turns. Payor mix quality, growth trajectory, and operational excellence further differentiate top-quartile outcomes from market averages.
In a market characterized by strong buyer demand, limited independent practice supply, and demographic tailwinds, well-positioned ophthalmology practices with thoughtful pre-market preparation may achieve premium valuations even in a normalized interest rate environment. Understanding these benchmarks provides the foundation for strategic decision-making, whether evaluating partnership opportunities today or building enterprise value for a future transaction.
Contact Eric Yetter ([email protected]) or Andy Snyder ([email protected]) today for a no-pressure conversation.
Andy Snyder
Managing Director
Andy Snyder
Managing Director
Whether you’re exploring a sale, raising capital, or simply want an outside perspective on where your business stands, our bankers are ready to listen. Reach out to start a confidential conversation with the FOCUS team.
